News

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 43^rd Annual Growth Stock Conference on Tuesday, June 6^th, at 10:00 a.m. CT

Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the Jefferies 2023 Healthcare Conference on Thursday, June 8, 2023, at approximately 11:30 a.m. (ET) at the New

Novocure (NASDAQ: NVCR) today announced that it will donate $3 million to Conquer Cancer^®, the ASCO Foundation, to advance cancer research and education.

Conquer Cancer is a global community of

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the Jefferies Global Healthcare Conference, June 7-9, 2023, in New York City.

In connection

Charles River Laboratories International, Inc. (NYSE: CRL) and Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO), today announced an agreement to implement RightSource

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today

Stockholders of Chemed Corporation (NYSE:CHE) today elected a slate of 10 directors at the Company’s 2023 annual stockholders’ meeting. New to the Board is Eileen McCarthy, Senior Vice President of

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2023. For the quarter, revenue was $1.03 billion, an increase of 12.6% from $913.9

Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at approximately 2:35 p.m. (ET)

Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors is evaluating potential strategic alternatives to enhance value

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the BofA Securities 2023 Healthcare Conference, May 9-11, 2023, in Las Vegas, Nevada.

In

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2023. Novocure is a global oncology company working to extend survival in some of the most aggressive forms

Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Bank of America Merrill Lynch 2023 Health Care Conference on Wednesday, May 10, 2023, at 10:40 AM (PDT) at

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Accugenix® Next Generation Sequencing for Bacterial Identification and Fungal Identification (Accugenix®

Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal year 2023 third quarter ended March 31, 2023 and provided

Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common

Novocure (NASDAQ: NVCR) today announced the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 American

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will

Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the first quarter ended March 31, 2023, on Wednesday, April 26, 2023, following the close of trading on the

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the first quarter ended March 31, 2023.

First Quarter Highlights

• 
  Revenue totaled $704.3 million, an

Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the

Novocure (NASDAQ: NVCR) today announced the 5^th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will